Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | SpringerLink
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
Cancers | Free Full-Text | Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell Lymphomas
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study | springermedizin.de
Presentazione di PowerPoint
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Treatment Groups and Common Treatment Regimens | Download Scientific Diagram
PDF) Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
The role of MRD in CLL
PCYC 2014.12.31 - 10-K
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
On the architecture of translational research designed to control chronic lymphocytic leukemia
JANSSEN | Business Wire
PDF) Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
ABBVIE: IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint | American Pharmacy News
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia - ScienceDirect
Frontiers | Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
régi Átlátni Szellőztetés pcyc 1130 illuminate trial presentation overall survival nacionalizmus körte Kábító
iLLUMINATE - Progression-Free Survival | IMBRUVICA® (ibrutinib) HCP
